# BE Study in Patients - Methotrexate Tablets

> **NCT02940561** · PHASE1 · UNKNOWN · sponsor: **Amneal Pharmaceuticals, LLC** · enrollment: 48 (estimated)

## Conditions studied

- Psoriasis
- Rheumatoid Arthritis

## Interventions

- **DRUG:** Methotrexate - Amneal
- **DRUG:** Methotrexate - DAVA

## Key facts

- **NCT ID:** NCT02940561
- **Lead sponsor:** Amneal Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-08
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2016-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02940561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02940561, "BE Study in Patients - Methotrexate Tablets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02940561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*